These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Early Prostate-Specific Antigen Changes and Clinical Outcome After Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687 [TBL] [Abstract][Full Text] [Related]
3. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer. Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954 [TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010 [No Abstract] [Full Text] [Related]
5. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056 [TBL] [Abstract][Full Text] [Related]
6. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006 [TBL] [Abstract][Full Text] [Related]
7. PSMA Theranostics: Current Status and Future Directions. Rahbar K; Afshar-Oromieh A; Jadvar H; Ahmadzadehfar H Mol Imaging; 2018; 17():1536012118776068. PubMed ID: 29873291 [TBL] [Abstract][Full Text] [Related]
8. Results of a Prospective Phase 2 Pilot Trial of Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003 [TBL] [Abstract][Full Text] [Related]
9. Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer. Gadot M; Davidson T; Aharon M; Atenafu EG; Malki A; Levartovsky M; Saad A; Domachevsky L; Berger R; Leibowitz R Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32357427 [TBL] [Abstract][Full Text] [Related]
10. Khreish F; Ebert N; Ries M; Maus S; Rosar F; Bohnenberger H; Stemler T; Saar M; Bartholomä M; Ezziddin S Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):721-728. PubMed ID: 31758224 [TBL] [Abstract][Full Text] [Related]
12. TheraP: a randomized phase 2 trial of Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341 [TBL] [Abstract][Full Text] [Related]
13. Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management. Kessel K; Bernemann C; Bögemann M; Rahbar K Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298770 [TBL] [Abstract][Full Text] [Related]
14. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431 [TBL] [Abstract][Full Text] [Related]